ArticleCommunications medicine2023

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial.

Manmeet S Ahluwalia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.